Are beta-lactams related to higher morbidity and mortality in urinary tract infections caused by extended-spectrum beta-lactamase-producing Escherichia coli?
You
J H S
JH
Kei
H W
HW
Lau
W C
WC
Wong
K Y
KY
Marasinghe
T
T
Lee
N
N
Ip
M
M
D000900:Anti-Bacterial Agents / Q000494:pharmacology / Q000627:therapeutic use*; D015780:Carbapenems / Q000494:pharmacology / Q000627:therapeutic use; D004926:Escherichia coli / Q000187:drug effects* / Q000201:enzymology / Q000302:isolation & purification; D004927:Escherichia coli Infections / Q000188:drug therapy* / Q000453:epidemiology / Q000382:microbiology; D006723:Hong Kong / Q000453:epidemiology; D006801:Humans; D012189:Retrospective Studies; D016896:Treatment Outcome; D014552:Urinary Tract Infections / Q000188:drug therapy* / Q000453:epidemiology / Q000382:microbiology; D018440:beta-Lactam Resistance; D001618:beta-Lactamases / Q000096:biosynthesis; D047090:beta-Lactams / Q000494:pharmacology / Q000627:therapeutic use*
D000900:Anti-Bacterial Agents; D015780:Carbapenems; D047090:beta-Lactams; D001618:beta-Lactamases